[go: up one dir, main page]

EE03471B1 - Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine - Google Patents

Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine

Info

Publication number
EE03471B1
EE03471B1 EE9800050A EE9800050A EE03471B1 EE 03471 B1 EE03471 B1 EE 03471B1 EE 9800050 A EE9800050 A EE 9800050A EE 9800050 A EE9800050 A EE 9800050A EE 03471 B1 EE03471 B1 EE 03471B1
Authority
EE
Estonia
Prior art keywords
active ingredient
dopamine agonist
composition
pharmaceutical composition
antacid
Prior art date
Application number
EE9800050A
Other languages
English (en)
Other versions
EE9800050A (et
Inventor
Stewart Johnson Edward
David Green Richard
Clarke Anthony
Original Assignee
R.P. Scherer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R.P. Scherer Limited filed Critical R.P. Scherer Limited
Publication of EE9800050A publication Critical patent/EE9800050A/et
Publication of EE03471B1 publication Critical patent/EE03471B1/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EE9800050A 1995-08-18 1996-08-16 Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine EE03471B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9517062.7A GB9517062D0 (en) 1995-08-18 1995-08-18 Pharmaceutical compositions
PCT/GB1996/002020 WO1997006786A1 (en) 1995-08-18 1996-08-16 Oral fast-dissolving compositions for dopamine agonists

Publications (2)

Publication Number Publication Date
EE9800050A EE9800050A (et) 1998-08-17
EE03471B1 true EE03471B1 (et) 2001-08-15

Family

ID=10779521

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800050A EE03471B1 (et) 1995-08-18 1996-08-16 Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine

Country Status (27)

Country Link
US (1) US6316027B1 (et)
EP (1) EP0850050B1 (et)
JP (1) JPH11511162A (et)
AT (1) ATE196249T1 (et)
AU (1) AU709641B2 (et)
BG (1) BG63188B1 (et)
BR (1) BR9610424A (et)
CA (1) CA2229597C (et)
CZ (1) CZ293129B6 (et)
DE (1) DE69610323T2 (et)
DK (1) DK0850050T3 (et)
EE (1) EE03471B1 (et)
ES (1) ES2151672T3 (et)
GB (1) GB9517062D0 (et)
GR (1) GR3034583T3 (et)
HU (1) HU222197B1 (et)
MX (1) MX9801305A (et)
NO (1) NO313368B1 (et)
NZ (1) NZ315740A (et)
PL (1) PL187718B1 (et)
PT (1) PT850050E (et)
RO (1) RO119066B1 (et)
RU (1) RU2189226C2 (et)
SK (1) SK283597B6 (et)
UA (1) UA64700C2 (et)
WO (1) WO1997006786A1 (et)
ZA (1) ZA967032B (et)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
ES2270517T3 (es) * 1997-05-19 2007-04-01 Zonagen, Inc. Terapia de combinacion para modular la respuesta sexual humana.
AU8805298A (en) 1997-07-01 1999-01-25 Implico B.V. Quick release compositions
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
GB9904911D0 (en) * 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
PL366204A1 (en) * 1999-12-30 2005-01-24 Tap Holdings, Inc. Oral mucosal dosage forms of apomorphine
CA2418915A1 (en) * 2000-08-08 2002-02-14 Teva Pharmaceutical Industries Ltd. Stable pergolide mesylate and process for making same
MXPA03001472A (es) * 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
AU2001294250A1 (en) * 2000-10-16 2002-04-29 Daiichi Pharmaceutical Co., Ltd. Medicinal compositions quickly disintegrating in the oral cavity and process forproducing the same
DE10107659B4 (de) * 2001-02-19 2008-03-13 Lts Lohmann Therapie-Systeme Ag Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
WO2003073988A2 (en) 2002-02-28 2003-09-12 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
CA2479372A1 (en) * 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
DE17154462T1 (de) 2002-04-05 2019-12-19 Euro-Celtique S.A. Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
WO2003092591A2 (en) * 2002-04-30 2003-11-13 Npd Llc Multi-phasic delivery via transmucosal absorption of antiemetic medicaments
EP1549323A2 (en) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
WO2004000223A2 (en) * 2002-06-20 2003-12-31 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
GB0226076D0 (en) * 2002-11-08 2002-12-18 Rp Scherer Technologies Inc Improved formulations containing substituted imidazole derivatives
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
BRPI0418228B8 (pt) * 2003-12-31 2021-05-25 Cima Labs Inc forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
JP5244318B2 (ja) * 2003-12-31 2013-07-24 シーマ・ラブス、インコーポレイテッド 発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法
US7576073B2 (en) 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
EP2397122B1 (en) * 2004-06-17 2014-05-14 Merz Pharma GmbH & Co. KGaA Formulations of neramexane dosage forms
CA2628298A1 (en) * 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state
EP1863455A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of parkinson's disease
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
US20070128285A1 (en) * 2005-07-12 2007-06-07 Chikara Jin Pharmaceutical composition for oral administration
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070105867A1 (en) * 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AR061485A1 (es) * 2006-06-15 2008-08-27 Serenex Inc Composiciones estabilizadas de tetraciclina
DE102006027793A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010019856A1 (en) * 2008-08-15 2010-02-18 The Mclean Hospital Corporation Methods and kits for treatings stroke and other neurological conditions
DE102009036285A1 (de) * 2008-10-13 2010-04-15 Illinois Tool Works Inc., Glenview Verfahren zur Herstellung eines Bohrers, insbesondere eines Gesteinsbohrers
US20100116281A1 (en) 2008-11-07 2010-05-13 Jerry Wayne Marshall Tobacco products and processes
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
HUE028121T2 (en) 2009-06-12 2016-11-28 Cynapsus Therapeutics Inc Sublingual apomorphine
WO2011026080A1 (en) 2009-08-31 2011-03-03 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
CA2776164C (en) 2009-10-01 2016-12-13 Aptalis Pharmatech, Inc. Orally administered corticosteroid compositions
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US10744086B2 (en) * 2009-10-30 2020-08-18 Ix Biopharma Ltd. Fast dissolving solid dosage form
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US9675102B2 (en) 2010-09-07 2017-06-13 R. J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
CN103347494A (zh) * 2010-10-08 2013-10-09 R·P·舍勒科技有限责任公司 使用淀粉的口服疫苗快速溶解剂型
HUE049349T2 (hu) 2010-12-16 2020-09-28 Sunovion Pharmaceuticals Inc Szublingvális filmek
US10881132B2 (en) 2011-12-14 2021-01-05 R.J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
EP4590072A3 (en) 2013-03-15 2025-11-05 RAI Strategic Holdings, Inc. Heating elements formed from a sheet of a material, inputs and methods for the production of atomizers, cartridge for an aerosol delivery device and method for assembling a cartridge for a smoking article
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US20160296463A1 (en) * 2013-11-11 2016-10-13 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods thereof
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US10611505B2 (en) 2015-05-04 2020-04-07 Rai Strategic Holdings, Inc. Dispensing machine for aerosol precursor
US10238145B2 (en) 2015-05-19 2019-03-26 Rai Strategic Holdings, Inc. Assembly substation for assembling a cartridge for a smoking article
US20170112194A1 (en) 2015-10-21 2017-04-27 Rai Strategic Holdings, Inc. Rechargeable lithium-ion capacitor for an aerosol delivery device
US10820630B2 (en) 2015-11-06 2020-11-03 Rai Strategic Holdings, Inc. Aerosol delivery device including a wirelessly-heated atomizer and related method
US10104912B2 (en) 2016-01-20 2018-10-23 Rai Strategic Holdings, Inc. Control for an induction-based aerosol delivery device
US10334880B2 (en) 2016-03-25 2019-07-02 Rai Strategic Holdings, Inc. Aerosol delivery device including connector comprising extension and receptacle
US11207478B2 (en) 2016-03-25 2021-12-28 Rai Strategic Holdings, Inc. Aerosol production assembly including surface with micro-pattern
US10405579B2 (en) 2016-04-29 2019-09-10 Rai Strategic Holdings, Inc. Methods for assembling a cartridge for an aerosol delivery device, and associated systems and apparatuses
US11019847B2 (en) 2016-07-28 2021-06-01 Rai Strategic Holdings, Inc. Aerosol delivery devices including a selector and related methods
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10477896B2 (en) 2016-10-12 2019-11-19 Rai Strategic Holdings, Inc. Photodetector for measuring aerosol precursor composition in an aerosol delivery device
US20180132529A1 (en) 2016-11-14 2018-05-17 Rai Strategic Holdings, Inc. Aerosol delivery device with integrated wireless connectivity for temperature monitoring
US20180132528A1 (en) 2016-11-14 2018-05-17 Rai Strategic Holdings, Inc. Photoelectric proximity sensor for gesture-based control of an aerosol delivery device
US10524508B2 (en) 2016-11-15 2020-01-07 Rai Strategic Holdings, Inc. Induction-based aerosol delivery device
US10537137B2 (en) 2016-11-22 2020-01-21 Rai Strategic Holdings, Inc. Rechargeable lithium-ion battery for an aerosol delivery device
PL3547858T3 (pl) 2016-12-01 2025-06-23 Rai Strategic Holdings, Inc. Ładowalny kondensator litowo-jonowy do urządzenia do wydawania aerozolu
CN119924598A (zh) 2016-12-02 2025-05-06 莱战略控股公司 用于气溶胶递送设备的感应充电
US11013266B2 (en) 2016-12-09 2021-05-25 Rai Strategic Holdings, Inc. Aerosol delivery device sensory system including an infrared sensor and related method
US10517326B2 (en) 2017-01-27 2019-12-31 Rai Strategic Holdings, Inc. Secondary battery for an aerosol delivery device
US10759554B2 (en) 2017-02-02 2020-09-01 Rai Strategic Holdings, Inc. Dispenser unit for aerosol precursor
US10827783B2 (en) 2017-02-27 2020-11-10 Rai Strategic Holdings, Inc. Digital compass for an aerosol delivery device
US10314340B2 (en) 2017-04-21 2019-06-11 Rai Strategic Holdings, Inc. Refillable aerosol delivery device and related method
US11297876B2 (en) 2017-05-17 2022-04-12 Rai Strategic Holdings, Inc. Aerosol delivery device
US10517330B2 (en) 2017-05-23 2019-12-31 RAI Stategic Holdings, Inc. Heart rate monitor for an aerosol delivery device
US11337456B2 (en) 2017-07-17 2022-05-24 Rai Strategic Holdings, Inc. Video analytics camera system for an aerosol delivery device
US10349674B2 (en) 2017-07-17 2019-07-16 Rai Strategic Holdings, Inc. No-heat, no-burn smoking article
US10791761B2 (en) 2017-08-17 2020-10-06 Rai Strategic Holdings, Inc. Microtextured liquid transport element for aerosol delivery device
US11039645B2 (en) 2017-09-19 2021-06-22 Rai Strategic Holdings, Inc. Differential pressure sensor for an aerosol delivery device
US10505383B2 (en) 2017-09-19 2019-12-10 Rai Strategic Holdings, Inc. Intelligent charger for an aerosol delivery device
US10660370B2 (en) 2017-10-12 2020-05-26 Rai Strategic Holdings, Inc. Aerosol delivery device including a control body, an atomizer body, and a cartridge and related methods
US12114688B2 (en) 2017-10-24 2024-10-15 Rai Strategic Holdings, Inc. Method for formulating aerosol precursor for aerosol delivery device
US10806181B2 (en) 2017-12-08 2020-10-20 Rai Strategic Holdings, Inc. Quasi-resonant flyback converter for an induction-based aerosol delivery device
US10555558B2 (en) 2017-12-29 2020-02-11 Rai Strategic Holdings, Inc. Aerosol delivery device providing flavor control
US10813385B2 (en) 2018-03-09 2020-10-27 Rai Strategic Holdings, Inc. Buck regulator with operational amplifier feedback for an aerosol delivery device
US11206864B2 (en) 2018-03-26 2021-12-28 Rai Strategic Holdings, Inc. Aerosol delivery device providing flavor control
US10959459B2 (en) 2018-05-16 2021-03-30 Rai Strategic Holdings, Inc. Voltage regulator for an aerosol delivery device
US11094993B2 (en) 2018-08-10 2021-08-17 Rai Strategic Holdings, Inc. Charge circuitry for an aerosol delivery device
US10939707B2 (en) 2018-08-23 2021-03-09 Rai Strategic Holdings, Inc. Aerosol delivery device with segmented electrical heater
US11614720B2 (en) 2018-11-19 2023-03-28 Rai Strategic Holdings, Inc. Temperature control in an aerosol delivery device
US11592793B2 (en) 2018-11-19 2023-02-28 Rai Strategic Holdings, Inc. Power control for an aerosol delivery device
US11753750B2 (en) 2018-11-20 2023-09-12 R.J. Reynolds Tobacco Company Conductive aerosol generating composite substrate for aerosol source member
US11547816B2 (en) 2018-11-28 2023-01-10 Rai Strategic Holdings, Inc. Micropump for an aerosol delivery device
US11096419B2 (en) 2019-01-29 2021-08-24 Rai Strategic Holdings, Inc. Air pressure sensor for an aerosol delivery device
US20200245696A1 (en) 2019-02-06 2020-08-06 Rai Strategic Holdings, Inc. Buck-boost regulator circuit for an aerosol delivery device
US11456480B2 (en) 2019-02-07 2022-09-27 Rai Strategic Holdings, Inc. Non-inverting amplifier circuit for an aerosol delivery device
US12140978B2 (en) 2019-03-01 2024-11-12 Rai Strategic Holdings, Inc. Temperature control circuitry for an aerosol delivery device
US11324249B2 (en) 2019-03-06 2022-05-10 R.J. Reynolds Tobacco Company Aerosol delivery device with nanocellulose substrate
BR112021017750A2 (pt) 2019-03-08 2021-11-16 Rai Strategic Holdings Inc Método para hidrólise de ácido lático para dispositivo de entrega de aerossol
US11200770B2 (en) 2019-04-02 2021-12-14 Rai Strategic Holdings, Inc. Functional control and age verification of electronic devices through visual communication
US11935350B2 (en) 2019-04-02 2024-03-19 Rai Strategic Holdings, Inc. Functional control and age verification of electronic devices through speaker communication
US11676438B2 (en) 2019-04-02 2023-06-13 Rai Strategic Holdings, Inc. Authentication and age verification for an aerosol delivery device
US11783395B2 (en) 2019-04-24 2023-10-10 Rai Strategic Holdings, Inc. Decentralized identity storage for tobacco products
US11690405B2 (en) 2019-04-25 2023-07-04 Rai Strategic Holdings, Inc. Artificial intelligence in an aerosol delivery device
US12232543B2 (en) 2019-05-17 2025-02-25 Rai Strategic Holdings, Inc. Age verification with registered cartridges for an aerosol delivery device
US12022859B2 (en) 2019-07-18 2024-07-02 R.J. Reynolds Tobacco Company Thermal energy absorbers for tobacco heating products
WO2021038493A1 (en) 2019-08-29 2021-03-04 Rai Strategic Holdings, Inc. Dual-chamber aerosol dispenser
GB201912686D0 (en) 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11785991B2 (en) 2019-10-04 2023-10-17 Rai Strategic Holdings, Inc. Use of infrared temperature detection in an aerosol delivery device
US11470689B2 (en) 2019-10-25 2022-10-11 Rai Strategic Holdings, Inc. Soft switching in an aerosol delivery device
JP7585322B2 (ja) 2019-11-18 2024-11-18 アール・エイ・アイ・ストラテジック・ホールディングス・インコーポレイテッド セキュリティタグ
CA3163451A1 (en) 2019-12-30 2021-07-08 Rai Strategic Holdings Inc A heart rate monitor for an aerosol delivery device
US12178258B2 (en) 2020-03-26 2024-12-31 Rai Strategic Holdings, Inc. Methods, apparatuses and systems for waking a device prior to device activation
US12484610B2 (en) 2020-04-16 2025-12-02 R.J. Reynolds Tobacco Company Aerosol delivery device including a segregated substrate
US20210321674A1 (en) 2020-04-21 2021-10-21 Rai Strategic Holdings, Inc. Pressure-sensing user interface for an aerosol delivery device
US11839240B2 (en) 2020-04-29 2023-12-12 Rai Strategic Holdings, Inc. Piezo sensor for a power source
WO2021250516A1 (en) 2020-06-08 2021-12-16 Nicoventures Trading Limited Effervescent oral composition comprising an active ingredient
US11771132B2 (en) 2020-08-27 2023-10-03 Rai Strategic Holdings, Inc. Atomization nozzle for aerosol delivery device
US11771136B2 (en) 2020-09-28 2023-10-03 Rai Strategic Holdings, Inc. Aerosol delivery device
EP4243796A4 (en) 2020-11-16 2025-01-22 Orcosa Inc. IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
US20220183389A1 (en) 2020-12-11 2022-06-16 Rai Strategic Holdings, Inc. Sleeve for smoking article
EP4326098A1 (en) 2021-04-22 2024-02-28 Nicoventures Trading Limited Effervescent oral composition
WO2024231554A1 (en) 2023-05-11 2024-11-14 Catalent U.K. Swindon Zydis Limited Increasing permeation for pre-gastric absorption of active pharmaceutical ingredients
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
EP4585059A1 (en) 2024-01-12 2025-07-16 Nicoventures Trading Limited Effervescent pouched product

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
DE3216869A1 (de) * 1982-05-03 1983-11-03 Schering AG, 1000 Berlin und 4709 Bergkamen Synergistische kombination mit zytostatischer wirkung
IT1200609B (it) * 1985-04-04 1989-01-27 Poli Ind Chimica Spa Composizione farmaceutice per il trattamento delle turbe cerebrovascolari e del cervello anziano
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
HU193780B (en) * 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
JPS63501717A (ja) * 1985-10-29 1988-07-14 ベーカー・カミンス・デルマトロジカルス・インコーポレーテッド 抗原誘発性アレルギ−反応を阻止するための方法および組成物
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
DE3631088A1 (de) * 1986-09-12 1988-06-23 Ferring Arzneimittel Gmbh Verwendung von opiat-antagonisten zur diagnose und therapie von hypothalamischen funktionsstoerungen
WO1993008699A1 (en) * 1991-11-04 1993-05-13 Fuisz Technologies Ltd. Water-soluble delivery systems for hydrophobic liquids
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE3831088A1 (de) * 1988-09-13 1990-03-15 Jochen Gasda Preisauszeichnungseinrichtung und verfahren zum aufbringen von preisauszeichnungen auf einen preisauszeichnungstraeger
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
WO1991004757A1 (en) 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
WO1993012769A1 (fr) * 1991-12-24 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. Preparation se desagrageant dans la bouche et elaboration de cette preparation
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
IL105553A (en) * 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage form comprising a porous network of matrix forming material which disperses rapidly in water
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
IL108366A (en) * 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
DE4320678C2 (de) 1993-06-22 1996-04-11 Branko Dipl Ing Klasnic Vorrichtung zum Entfernen von Rechengut aus einer mit einer verunreinigten Flüssigkeit durchströmten Zulaufrinne, insbesondere von Kläranlagen
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
PL187718B1 (pl) 2004-09-30
NO980669L (no) 1998-04-17
UA64700C2 (en) 2004-03-15
NO313368B1 (no) 2002-09-23
HUP9900183A3 (en) 1999-11-29
ES2151672T3 (es) 2001-01-01
NZ315740A (en) 1999-06-29
BG63188B1 (bg) 2001-06-29
HU222197B1 (hu) 2003-05-28
ZA967032B (en) 1997-03-04
CA2229597C (en) 2004-02-10
PL324988A1 (en) 1998-07-06
CZ45598A3 (cs) 1998-07-15
AU6750996A (en) 1997-03-12
EP0850050B1 (en) 2000-09-13
RO119066B1 (ro) 2004-03-30
HUP9900183A2 (hu) 1999-05-28
DK0850050T3 (da) 2000-10-16
CA2229597A1 (en) 1997-02-27
US6316027B1 (en) 2001-11-13
DE69610323D1 (de) 2000-10-19
NO980669D0 (no) 1998-02-17
EP0850050A1 (en) 1998-07-01
SK19198A3 (en) 1998-09-09
BR9610424A (pt) 1999-03-30
GB9517062D0 (en) 1995-10-25
GR3034583T3 (en) 2001-01-31
SK283597B6 (sk) 2003-10-07
WO1997006786A1 (en) 1997-02-27
RU2189226C2 (ru) 2002-09-20
CZ293129B6 (cs) 2004-02-18
JPH11511162A (ja) 1999-09-28
AU709641B2 (en) 1999-09-02
DE69610323T2 (de) 2001-02-22
ATE196249T1 (de) 2000-09-15
BG102254A (en) 1998-10-30
MX9801305A (es) 1998-05-31
EE9800050A (et) 1998-08-17
PT850050E (pt) 2001-01-31

Similar Documents

Publication Publication Date Title
EE03471B1 (et) Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
YU35893A (sh) Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba
KR930007439A (ko) 방출 조절형 제약 조성물
AU780011B2 (en) Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
RU99117926A (ru) Лекарственные формы и способ лечения расстройства мужской эректильной функции
NO20000466D0 (no) Farmasoeytisk preparat for sure, lipofile forbindelser i form av en selvemulgerende formulering
HUP0003405A2 (hu) Szabályozott hatóanyag-leadású, szublingvális vagy bukkális adagolású gyógyszerkészítmények
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
GB9901819D0 (en) Pharmaceutical compositions
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
IL179718A0 (en) Pharmaceutical composition containing irbesartan
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
MXPA05008921A (es) Formulaciones orales semisolidas para liberacion inmediata que comprenden un agente hidrofobo anticancer, un glicerido poliglicolisado y un vehiculo hidrofilo.
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
Zanin et al. Sex difference in sensitization to the locomotor effects of mazindol in rats
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
DK0483320T3 (da) Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf
YU70493A (sh) Stabilan vodeno rastvoran veterinarski preparat i postupak za njegovo dobijanje
TW200621314A (en) Methods and formulations for making pharmaceutical compositions containing bupropion
MY102368A (en) Solid sustained-release composition

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130816